High-Alert and LASA Medication Controls: Building Your Own Lists

Start with the formulary itself, item by item, and apply two questions to each: if this were given in error, at the wrong dose or to the wrong patient, could it cause serious harm quickly; and does our hospital actually stock it. The classes that reliably survive this filter in a general hospital are insulins, anticoagulants including heparin and low molecular weight heparins, concentrated electrolytes especially potassium chloride, neuromuscular blocking agents, opioids and other controlled substances, chemotherapeutic agents, and concentrated vasoactive infusions.

Then layer your own data over it. Pull the last two years of medication incident reports and pharmacy interventions and see which products actually generate events in your hospital. This frequently surfaces something the published lists do not emphasise, such as a paediatric formulation that requires an unusual dilution, or an agent that arrives in two strengths from two suppliers. A list built from published sources alone will miss precisely the local hazards that your own reports are already telling you about.

Keep the list short enough to be meaningful. A high-alert list of ninety items produces the same behaviour as no list at all, because staff cannot treat ninety products as exceptional. If the list is growing past what a nurse could recall, the controls have become undifferentiated, and it is time to tier it: a small set with the full control package including independent double checks, and a wider set with labelling and storage controls only. Sign the list off through the pharmacy and therapeutics committee so it carries clinical authority rather than pharmacy preference.

The published confused drug name lists are useful for the internationally recognised pairs, and they are built on names, not on the boxes sitting in your store. Indian hospitals stock a large number of brand names across multiple suppliers, and a LASA risk in your hospital may be two brands from the same manufacturer with near-identical packaging that appears on no published list anywhere. The only way to find these is to walk the store and the ward cupboards with the pharmacist and look.

Run the search in three passes. First, generic names that resemble each other in speech or writing. Second, brand names that resemble each other, which in the Indian market is the larger category. Third, packaging and presentation similarity regardless of name: same colour scheme, same ampoule size, same font, adjacent shelf position. That third pass finds pairs the name-based lists never will, and it is the one most hospitals skip because it requires physically standing in the store.

Refresh the list whenever procurement changes a supplier, not annually. A new supplier for a routine injectable can introduce a packaging similarity overnight, and the ward staff who have handled the old presentation for three years are exactly the people who will pick up the new one without reading it. Build a check into the procurement process: before a new product is stocked, the pharmacist assesses it against existing stock for look-alike risk and records the outcome. That single control catches most new LASA pairs before they reach a patient.

Tall man lettering differentiates confusable names by capitalising the letters that differ, so that similar names become visually distinct at a glance. The published lists maintained by ISMP and referenced by regulators give the standard formats for internationally recognised pairs, and for local pairs you apply the same principle: capitalise the dissimilar segment, not the shared one. The mistake is capitalising the beginning of both names, which are usually the parts that are the same and therefore carries no information.

Apply it everywhere the name appears, and that list is longer than most hospitals realise: shelf labels, bin labels, pharmacy dispensing labels, the order entry screen, the medication administration record, and the printed drug chart. Applying it on the pharmacy shelf and nowhere else creates a control that operates in the one place where a trained pharmacist is already checking, and is absent in the ward where the confusion actually occurs.

Be honest about its limits. Tall man lettering is a labelling intervention and labelling interventions sit in the middle of the effectiveness hierarchy at best. It helps a person who is reading; it does nothing for a person who is reaching by habit for the familiar position on a shelf. It should always be paired with a physical control such as separation, and it should never be presented to a committee as having solved a LASA risk on its own.

The most effective control available for LASA pairs is also the cheapest: do not store them next to each other. Physical separation, with an intervening product or a different shelf, defeats the reach-by-position error that labelling cannot touch. Add a visual differentiator such as a coloured shelf label or a bin divider, and mark the storage location itself rather than relying on the product packaging, which you do not control.

Concentrated electrolytes deserve their own rule and it should be absolute. Concentrated potassium chloride, hypertonic saline above the routine concentration, and concentrated sodium bicarbonate should not be held in general ward stock at all. Supply them from pharmacy as ready-diluted preparations wherever the clinical use permits, and where undiluted stock is genuinely required in a critical care area, hold it in a separately locked location with its own inventory count and a warning label applied at the point of storage. This is the classic example of removing the possibility of an error rather than warning against it.

Segregation has an operational cost and it is worth acknowledging. Ward staff dislike it because it slows retrieval, pharmacy dislike it because it complicates stock counts, and the first three months after implementation generate genuine complaints. Hold the line, and measure the alternative honestly: a hospital that reverts to alphabetical storage for convenience has traded a real safety control for a few seconds per dose. Audit storage compliance by walking the wards, not by asking whether the policy exists.

An independent double check means two people separately verify the same thing without either seeing or hearing the other's conclusion first. What happens in most hospitals is a witnessed check: one nurse prepares the dose, says what it is, and the second nurse confirms. That is confirmation bias with two signatures on it, and its detection rate is far lower than the process it is documented as being. The word independent is doing all the work in the phrase and it is the word most often ignored.

Doing it properly means the second checker performs the calculation themselves from the original order, without being told the first result, and only then do the two compare. It takes longer, it requires two people to be available at the same moment, and it fails when the ward is short-staffed at two in the morning. Because it is expensive, it should be reserved for a small number of situations where it earns its cost: paediatric and neonatal dose calculations, insulin, concentrated infusions, chemotherapy, and neuromuscular blocking agents.

Applying it to twenty medication categories guarantees it will be performed nominally rather than actually, and a control performed nominally is worse than none because it creates false assurance. Audit the practice by observation, not by counting signatures on charts, and expect the first audit to be uncomfortable. Where electronic prescribing and barcode verification are available, they replace part of this burden more reliably than a human second check does, and a system such as HealUDoc can carry the order, the calculated dose and the administration record on one trail so the verification does not depend on two people finding each other.

The lists decay unless something feeds them. The feed is your own medication error and near miss reporting, and it needs a specific field capturing which product was involved and whether a LASA or high-alert factor contributed. Without that field the reports arrive as narrative and nobody has the time to read two years of free text looking for patterns. With it, the quarterly review takes an hour and produces additions to the list that are grounded in what actually happened in your building.

Review formally through the pharmacy and therapeutics committee at least annually, and immediately whenever procurement changes a product, a new strength is introduced, or an incident implicates a pair not currently listed. Record the review date and the decisions in the committee minutes, because the assessor question is rarely whether you have a list; it is when you last reviewed it and what changed. A list dated three years ago in a hospital that has changed suppliers twice answers that question badly.

Close the loop with the wards. Circulate additions and removals with a one-line reason, and where a pair was added because of a near miss on a specific ward, tell that ward that their report produced the change. Medication safety controls are among the few areas where the connection between a report and a visible change can be made concrete within weeks, and hospitals that make that connection visible find their medication error reporting rate climbs, which is exactly the direction it should move in.